Genetic enhancement of stem cell engraftment, survival, and efficacy.

@article{Penn2008GeneticEO,
  title={Genetic enhancement of stem cell engraftment, survival, and efficacy.},
  author={Marc S. Penn and Abeel A. Mangi},
  journal={Circulation research},
  year={2008},
  volume={102 12},
  pages={
          1471-82
        }
}
Cell-based therapies for the prevention and treatment of cardiac dysfunction offer the potential to significantly modulate cardiac function and improve outcomes in patients with cardiovascular disease. To date several clinical studies have suggested the potential efficacy of several different stem cell types; however, the benefits seen in clinical trials have been inconsistent and modest. In parallel, preclinical studies have identified key events in the process of cell-based myocardial repair… Expand
Stem and progenitor cell-based therapy in ischaemic heart disease: promise, uncertainties, and challenges.
TLDR
Further optimization of cell-based therapy is urgently needed, and finally, large-scale clinical trials are required to eventually proof its clinical efficacy with respect to outcomes, i.e. morbidity and mortality. Expand
Pharmacologic and genetic strategies to enhance cell therapy for cardiac regeneration.
TLDR
Given the promise of therapeutic interventions to enhance the regenerative capacity of multipotent stem cells as well as specifically guide endogenous or exogenous stem cells into a cardiac lineage, their application in cardiac regenerative medicine should be the focus of future clinical research. Expand
Cell therapy for cardiac repair—lessons from clinical trials
TLDR
The experience obtained from trials of 'first-generation' cell-based therapy is summarized, and the advances in the purification and lineage specification of stem cells that have enabled the development of 'next- generation' stem-cell-based therapies targeting cardiovascular disease are emphasized. Expand
Cardiac Stem Cell Therapy for Cardiac Repair
TLDR
The first clinical trial of autologous CSCs for treatment of heart failure resulting from ischemic heart disease has been conducted, and the interim results are quite promising, and warrant larger, phase II studies. Expand
Therapy with c-kitPOS Cardiac Stem Cells for Ischemic Cardiomyopathy
TLDR
Administration of autologous CSCs to patients with ischemic heart failure was found to be safe and feasible, and CSC-treated patients exhibited a significant improvement in cardiac function, as well as a reduction in scar size and an improvement in quality of life. Expand
Regenerative strategies for preserving and restoring cardiac function.
TLDR
The discussion is begun that the best future therapeutic option to regenerate end organ function will be a combination of programmed stem cells and biopharmaceuticals that modulate regenerative signaling to bolster the natural in vivo cellular and signaling mechanisms. Expand
Cell-Based Therapy in Ischemic Heart Disease
TLDR
To optimize and fully leverage the regenerative potential of cell-based therapies further aspects including identification of a potentially ideal cell linage as well as timing, repetition and dosing of cell delivery need to be addressed. Expand
Mesenchymal stem cell therapy for heart disease.
TLDR
This review will focus on the current understanding of MSC biology and MSC mechanism of action in cardiac repair, which can be harnessed to both prevent and reverse remodeling in the ischemically injured ventricle. Expand
Challenges and Strategies for Improving the Regenerative Effects of Mesenchymal Stromal Cell-Based Therapies
TLDR
A perspective on whether mesenchymal stromal cell-derived extracellular vesicle delivery, as a cell-free regenerative approach, may circumvent current cell therapy limitations is provided. Expand
Cell Therapy for Heart Failure: A Comprehensive Overview of Experimental and Clinical Studies, Current Challenges, and Future Directions
TLDR
A critically review of the large body of work performed with respect to the use of stem/progenitor cells in HF, both at the experimental and clinical levels, and to discuss current controversies, unresolved issues, challenges, and future directions. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 112 REFERENCES
Targeted gene therapy for the treatment of cardiac dysfunction.
TLDR
This review will discuss the vectors and mechanisms of gene delivery as well as potential molecular targets for the treatment of CHF. Expand
Stem-cell therapy for cardiac disease
TLDR
In conclusion, resident cardiac stem cells have been shown to differentiate into multiple cell types present in the heart, including cardiac muscle cells, indicating that the heart is not terminally differentiated. Expand
Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction.
TLDR
The results of a randomized study of bone-marrow-derived mesenchymal stem cells, administered to pigs, which offer several new insights regarding cellular cardiomyoplasty demonstrate that the direct injection of cellular grafts into damaged myocardium is safe and effective in the perii-nfarct period. Expand
Regenerating the heart
TLDR
Future research is likely to focus on improving the ability to guide the differentiation of stem cells, control their survival and proliferation, identify factors that mediate their homing and modulate the heart's innate inflammatory and fibrotic responses. Expand
Human cardiac stem cells exhibit mesenchymal features and are maintained through Akt/GSK-3beta signaling.
TLDR
It is concluded that hCSCs exhibit mesenchymal features and that Akt/GSK-3beta may be crucial modulators for hC SC maintenance in human heart. Expand
SDF-1 Recruits Cardiac Stem Cell-Like Cells that Depolarize In Vivo
TLDR
This study suggests that the prolongation of SDF-1 expression at the time of acute MI leads to the recruitment of endogenous cardiac myosin stem cells that may represent cardiac stem cells which are capable of depolarizing and thus may contribute to increased contractile function even in the absence of maturation into a mature cardiac myocyte. Expand
Mechanical and electrical effects of cell-based gene therapy for ischemic cardiomyopathy are independent.
TLDR
Transient reestablishment of stem cell homing via transplantation of modified SKMBs is sufficient to improve cardiac function, however, despite improved mechanical function, the risk of ventricular tachycardia increased. Expand
Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy
TLDR
It is shown that Stromal-cell-derived factor 1 (SDF-1) is sufficient to induce therapeutic stem-cell homing to injured myocardium and suggested a strategy for directed stem- cell engraftment into injured tissues. Expand
Engineered Cell Therapy for Sustained Local Myocardial Delivery of Nonsecreted Proteins
TLDR
The data suggest a viable strategy for the delivery of proteins that are not naturally secreted or internalized, and provide the first insight into the feasibility and effectiveness of cell-penetrating proteins combined with cell transplantation in the heart. Expand
Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts
TLDR
Mesenchymal stem cells genetically enhanced with Akt1 can repair infarcted myocardium, prevent remodeling and nearly normalize cardiac performance. Expand
...
1
2
3
4
5
...